Tags

Type your tag names separated by a space and hit enter

Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients.
Am J Transl Res. 2019; 11(12):7456-7470.AJ

Abstract

We aimed to compare the treatment response, survivals and safety of drug-eluting bead (DEB) transarterial chemoembolization (TACE) with CalliSpheres® microspheres (CSM) and conventional TACE (cTACE) as first-line treatment in Chinese HCC patients. 192 HCC patients from multiple centers received DEB-TACE with CSM or cTACE treatment as first-line treatment were included and assigned to DEB-TACE group (N=94) or cTACE group (N=98) accordingly. Treatment response was assessed at 1 month (M1), M3 and M6 after treatment. Progression-free survival (PFS) and overall survival (OS) was evaluated. Liver function indexes and adverse events were recorded. Complete response (CR) and objective response rate (ORR) were higher, while disease control rate (DCR) rate was similar in DEB-TACE group compared with cTACE group, and further multivariate logistic regression analysis validated that DEB-TACE vs cTACE independently predicted higher ORR. For survivals, no difference in PFS or OS was observed between DEB-TACE and cTACE groups, and multivariate Cox's proportional hazards regression revealed that DEB-TACE vs cTACE was not correlated with PFS or OS either. Additionally, no difference in liver function indexes at M1 or changes of liver function indexes from M0 to M1 between DEB-TACE and cTACE groups after treatment was observed, whereas DEB-TACE resulted in higher incidence of pain and fever during treatment or hospitalization. DEB-TACE with CSM discloses better treatment response, similar survival profiles and equal liver function injury but increased incidence of short-term adverse events than cTACE as the first-line therapy in treating HCC patients.

Authors+Show Affiliations

Department of Interventional Therapy, Guangxi Medical University Affiliated Tumor Hospital China.Department of Interventional Therapy, Guangxi Medical University Affiliated Tumor Hospital China.Department of Radiology, Renmin Hospital of Wuhan University, Hubei General Hospital China.Department of Radiology, Xiangya Hospital Central South University China.Department of Radiology, Xiangya Hospital Central South University China.Department of Intervention, Hunan Provincial People's Hospital China.Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology China.Department of Radiology, The Second Xiangya Hospital of Central South University Changsha, China.Department of Radiology, Wuhan General Hospital of Guangzhou Military China.Department of Radiology, Wuhan General Hospital of Guangzhou Military China.Department of Intervention, Hunan Provincial People's Hospital China.Department of Radiology, Renmin Hospital of Wuhan University, Hubei General Hospital China.Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology China.Department of Radiology, Zhongnan Hospital of Wuhan University Wuhan, China.Department of Radiology, The Second Xiangya Hospital of Central South University Changsha, China.Department of Radiology, Zhongnan Hospital of Wuhan University Wuhan, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31934293

Citation

Ma, Yilong, et al. "Comparison of Treatment Efficacy and Safety Between Drug-eluting Bead Transarterial Chemoembolization With CalliSpheres® Microspheres and Conventional Transarterial Chemoembolization as First-line Treatment in Hepatocellular Carcinoma Patients." American Journal of Translational Research, vol. 11, no. 12, 2019, pp. 7456-7470.
Ma Y, Zhao C, Zhao H, et al. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients. Am J Transl Res. 2019;11(12):7456-7470.
Ma, Y., Zhao, C., Zhao, H., Li, H., Chen, C., Xiang, H., Zheng, C., Ma, C., Luo, C., Qiu, H., Yao, Y., Hu, H., Xiong, B., Zhou, J., Zhu, H., & Long, Q. (2019). Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients. American Journal of Translational Research, 11(12), 7456-7470.
Ma Y, et al. Comparison of Treatment Efficacy and Safety Between Drug-eluting Bead Transarterial Chemoembolization With CalliSpheres® Microspheres and Conventional Transarterial Chemoembolization as First-line Treatment in Hepatocellular Carcinoma Patients. Am J Transl Res. 2019;11(12):7456-7470. PubMed PMID: 31934293.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients. AU - Ma,Yilong, AU - Zhao,Chang, AU - Zhao,Hui, AU - Li,Haiping, AU - Chen,Changyong, AU - Xiang,Hua, AU - Zheng,Chuansheng, AU - Ma,Cong, AU - Luo,Chao, AU - Qiu,Huaiming, AU - Yao,Yuanhui, AU - Hu,Hongyao, AU - Xiong,Bin, AU - Zhou,Jun, AU - Zhu,Hui, AU - Long,Qingyun, Y1 - 2019/12/15/ PY - 2018/09/16/received PY - 2018/12/29/accepted PY - 2020/1/15/entrez PY - 2020/1/15/pubmed PY - 2020/1/15/medline KW - DEB-TACE KW - HCC KW - safety KW - survival profiles KW - tumor response SP - 7456 EP - 7470 JF - American journal of translational research JO - Am J Transl Res VL - 11 IS - 12 N2 - We aimed to compare the treatment response, survivals and safety of drug-eluting bead (DEB) transarterial chemoembolization (TACE) with CalliSpheres® microspheres (CSM) and conventional TACE (cTACE) as first-line treatment in Chinese HCC patients. 192 HCC patients from multiple centers received DEB-TACE with CSM or cTACE treatment as first-line treatment were included and assigned to DEB-TACE group (N=94) or cTACE group (N=98) accordingly. Treatment response was assessed at 1 month (M1), M3 and M6 after treatment. Progression-free survival (PFS) and overall survival (OS) was evaluated. Liver function indexes and adverse events were recorded. Complete response (CR) and objective response rate (ORR) were higher, while disease control rate (DCR) rate was similar in DEB-TACE group compared with cTACE group, and further multivariate logistic regression analysis validated that DEB-TACE vs cTACE independently predicted higher ORR. For survivals, no difference in PFS or OS was observed between DEB-TACE and cTACE groups, and multivariate Cox's proportional hazards regression revealed that DEB-TACE vs cTACE was not correlated with PFS or OS either. Additionally, no difference in liver function indexes at M1 or changes of liver function indexes from M0 to M1 between DEB-TACE and cTACE groups after treatment was observed, whereas DEB-TACE resulted in higher incidence of pain and fever during treatment or hospitalization. DEB-TACE with CSM discloses better treatment response, similar survival profiles and equal liver function injury but increased incidence of short-term adverse events than cTACE as the first-line therapy in treating HCC patients. SN - 1943-8141 UR - https://www.unboundmedicine.com/medline/citation/31934293/Comparison_of_treatment_efficacy_and_safety_between_drug_eluting_bead_transarterial_chemoembolization_with_CalliSpheres®_microspheres_and_conventional_transarterial_chemoembolization_as_first_line_treatment_in_hepatocellular_carcinoma_patients_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31934293/ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.